ADXN vs. RNXT, AKTX, IXHL, LSTA, CGTX, CVM, INKT, KALA, MRNS, and UBX
Should you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include RenovoRx (RNXT), Akari Therapeutics (AKTX), Incannex Healthcare (IXHL), Lisata Therapeutics (LSTA), Cognition Therapeutics (CGTX), CEL-SCI (CVM), MiNK Therapeutics (INKT), KALA BIO (KALA), Marinus Pharmaceuticals (MRNS), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry.
Addex Therapeutics vs.
RenovoRx (NASDAQ:RNXT) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
RenovoRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
RenovoRx has higher earnings, but lower revenue than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.
Addex Therapeutics has a net margin of 850.30% compared to RenovoRx's net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat RenovoRx's return on equity.
3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 7.1% of RenovoRx shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Addex Therapeutics received 6 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 51.72% of users gave Addex Therapeutics an outperform vote while only 47.37% of users gave RenovoRx an outperform vote.
RenovoRx currently has a consensus target price of $6.50, indicating a potential upside of 322.08%. Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 284.07%. Given RenovoRx's higher possible upside, analysts clearly believe RenovoRx is more favorable than Addex Therapeutics.
In the previous week, Addex Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 1 mentions for Addex Therapeutics and 0 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.00 beat Addex Therapeutics' score of -0.25 indicating that RenovoRx is being referred to more favorably in the media.
Summary
Addex Therapeutics beats RenovoRx on 11 of the 16 factors compared between the two stocks.
Get Addex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Addex Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADXN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ADXN Stock Alerts